[Concerning the significance of paraoxonase-1 and SR-B1 genes in atherosclerosis].
High-density lipoprotein (HDL) is an independent protective factor against cardiovascular disease. The enzyme paraoxonase-1 (PON-1) contributes to the anti-atherogenic effects of HDL. In vitro studies have demonstrated that paraoxonase's substrates are highly heterogeneous and that some contribute to the development of atherosclerotic lesions. The atheroprotective role of PON-1 was established in genetically engineered animal models. In humans, the PON-1 Gln192Arg and Met55Leu polymorphisms appear to be associated with increased susceptibility to cardiovascular disease and with different PON-1 activity levels and concentrations. The CLA-1 (CD36 and Lysosomal integral membrane protein-II Analogous-1) gene is the human homologue of the murine SR-B1 (Scavenger Receptor class B type 1) gene. SR-B1 was the first high-affinity HDL receptor to be identified at the molecular level. The CLA-1 receptor plays a pivotal role in HDL-mediated reverse cholesterol transport by mediating the selective uptake of free cholesterol as well as of native and oxidized cholesteryl esters. Its atheroprotective role has also been established in transgenic mice studies. Several polymorphic variants of the CLA-1 gene have been described, some of which are associated with phenotypic changes in plasma lipoproteins. Both genes participate in the complex HDL metabolic pathway and, presumably, also in defense mechanisms against oxidative stress.
Unidad de Investigación, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España.
Francisco
F
Rodríguez Esparragón
Yaridé
Y
Hernández Trujillo
Antonio
A
Macías Reyes
Enrique
E
Hernández Ortega
Alfonso
A
Medina
José C
JC
Rodríguez Pérez
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000235:genetics*; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002784:Cholesterol / Q000378:metabolism; D002788:Cholesterol Esters / Q000378:metabolism; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D006710:Homocysteine / Q000097:blood / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000235:genetics; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D018384:Oxidative Stress; D010641:Phenotype; D011110:Polymorphism, Genetic; D018110:Receptors, Lipoprotein; D051122:Scavenger Receptors, Class B / Q000235:genetics*
D000924:Anticholesteremic Agents; D002788:Cholesterol Esters; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D018110:Receptors, Lipoprotein; D051122:Scavenger Receptors, Class B; C031616:high density lipoprotein receptors; D006710:Homocysteine; D002784:Cholesterol; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human